Expression of mos in Ependymal Gliomas

American Journal of Clinical Pathology

Volumn 120, Issue 5, 2003, Pages 699-705

  Athanasiou, Athanasios ^a   Perunovic, Branko ^a,c   Quilty, Robert D ^a   Gorgoulis, Vassilis G ^b   Kittas, Christos ^b   Love, Seth ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Brain neoplasms; c mos; Cell cycle; Ependymoma; Human; Immunohistochemistry; Proto oncogene proteins

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY KI 67; ONCOPROTEIN; PROTEIN MOS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPENDYMOMA; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; LABELING INDEX; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; STATISTICAL SIGNIFICANCE;

EID: 0242332147     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/DL2TLDJG7JB1BQ72     Document Type: Article

References (36)

1. Singh B, Arlinghaus RB. Mos and the cell cycle. Prog Cell Cycle Res. 1997;3:251-259.
2. Sagata N. What does mos do in oocytes and somatic cells? Bioessays. 1997;19:13-21.
3. Yew N, Strobel M, Vande Woude GF. Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr Opin Genet Dev. 1993;3:19-25.
4. Herzog NK, Ramagli LS, Khorana S, et al. Evidence for somatic cell expression of the c-mos protein [corrected] [published correction appears in Oncogene. 1990;5:623]. Oncogene. 1989;4:1307-1315.
5. Herzog NK, Ramagli LS, Khorana S, et al. Evidence for somatic cell expression of the c-mos protein [corrected] [published correction appears in Oncogene. 1990;5:623]. Oncogene. 1989;4:1307-1315.
6. Propst F, Rosenberg MP, Iyer A, et al. c-mos proto-oncogene RNA transcripts in mouse tissues: structural features, developmental regulation, and localization in specific cell types. Mol Cell Biol. 1987;7:1629-1637.
7. Li CC, Chen E, O'Connell CD, et al. Detection of c-mos proto-oncogene expression in human cells. Oncogene. 1993;8:1685-1691.
8. Papkoff J, Verma IM, Hunter T. Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell. 1982;29:417-426.
9. Fukasawa K, Vande Woude GF. Synergy between the mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol. 1997;17:506-518.
10. Blair DG, McClements WL, Oskarsson MK, et al. Biological activity of cloned Moloney sarcoma virus DNA: terminally redundant sequences may enhance transformation efficiency. Proc Natl Acad Sci U S A. 1980;77:3504-3508.
11. Fukasawa K, Murakami MS, Blair DG, et al. Similarities between somatic cells overexpressing the mos oncogene and oocytes during meiotic interphase. Cell Growth Differ. 1994;5:1093-1103.
12. Fukasawa K, Vande Woude GF. mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc Natl Acad Sci U S A. 1995;92:3430-3434.
13. Okazaki K, Nishizawa M, Furuno N, et al. Differential occurrence of CSF-like activity and transforming activity of mos during the cell cycle in fibroblasts. EMBO J. 1992;11:2447-2456.
14. Yang Y, Pham CD, Arlinghaus RB, et al. Elevated level of cyclin D1 in mos-transformed cells. Int J Oncol. 1998;12:1199-1202.
15. Athanasiou A, Gorgoulis VG, Zacharatos P, et al. c-mos immunoreactivity is an indicator of good prognosis in lung cancer. Histopathology. 2000;37:45-54.
16. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics. Cancer Res. 2001;61:538-549.
17. Perunovic B, Athanasiou A, Quilty RD, et al. Expression of mos in astrocytic tumors and its potential role in neoplastic progression. Hum Pathol. 2002;33:703-707.
18. Wiestler OD, Schiffer D, Coons SW, et al. Ependymal tumours. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000:71-82. World Health Organization Classification of Tumours.
19. Sato K, Schauble B, Kleihues P, et al. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer. 1996;66:305-308.
20. Fink KL, Rushing EJ, Schold SC, et al. Infrequency of p53 gene mutations in ependymomas. J Neurooncol. 1996;27:111-115.
21. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol. 1997;7:807-822.
22. Nozaki M, Tada M, Matsumoto R, et al. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol (Berl). 1998;95:291-296.
23. Zhou XP, Li YJ, Hoang X, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer. 1999;84:150-154.
24. Bortolotto S, Chiado P, Cavalla P, et al. CDKN2A/p16 in ependymomas. J Neurooncol. 2001;54:9-13.
25. Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol. 1998;24:434-440.
26. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol. 1999;3:11-18.
27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
28. Kalbfleish J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
29. Zacharatos P, Kotsinas A, Tsantoulis P, et al. Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas. Mol Med. 2001;7:590-597.
30. Parkar MH, Seid JM, Stringer BM, et al. Abnormal expression of the mos proto-oncogene in human thyroid medullary carcinoma. Cancer Lett. 1988;43:185-189.
31. Xerri L, Charpin C, Hassoun J, et al. mos oncogene expression in human ovarian tumors. Anticancer Res. 1991;11:1629-1634.
32. Stenman G, Sahlin P, Mark J, et al. Structural alterations of the c-mos locus in benign pleomorphic adenomas with chromosome abnormalities of 8q12. Oncogene. 1991;6:1105-1108.
33. de Foy KA, Gayther SA, Colledge WH, et al. Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas. Br J Cancer. 1998;77:1642-1644.
34. Wang XM, Yew N, Peloquin JG, et al. mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression. Proc Natl Acad Sci U S A. 1994;91:8329-8333.
35. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors: NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. 1999;155:627-632.
36. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog. 1993;8:74-80.